长春高新(000661.SZ)放量跌停:Q3预期下调,新患入组不及预期
格隆汇9月14日丨超1500亿市值的长春高新(000661.SZ)今日放量跌停报3781.62元,成交额放大至58亿元,创7月底以来新高,截至收盘跌停封单达1.17万手,这意味着还有超4亿资金等着出逃,该股现价较今年8月4日创出的历史最高价513.5元下跌27.6%,最新市值1504亿元。龙头、高价股出现放量跌停,引起市场高度关注,市场担忧这是高价股或者说前期涨幅较大的蓝筹股出现拐点的信号。针对股价大跌,长春高新相关人士午间表示,公司生产经营一切正常,百克生物分拆上市事宜正在稳步推进中。但有市场人士指出,今日大跌主要是因为Q3预期下调,新患入组不及预期。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.